246 related articles for article (PubMed ID: 25311767)
1. Who dies from prostate cancer?
Patrikidou A; Loriot Y; Eymard JC; Albiges L; Massard C; Ileana E; Di Palma M; Escudier B; Fizazi K
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):348-52. PubMed ID: 25311767
[TBL] [Abstract][Full Text] [Related]
2. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
3. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.
Pond GR; Sonpavde G; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
Eur Urol; 2014 Jan; 65(1):3-6. PubMed ID: 24120464
[TBL] [Abstract][Full Text] [Related]
4. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience.
Afshar M; Evison F; James ND; Patel P
Urol Oncol; 2015 Aug; 33(8):338.e1-7. PubMed ID: 26059077
[TBL] [Abstract][Full Text] [Related]
5. The impact of time to metastasis on overall survival in patients with prostate cancer.
Frees S; Akamatsu S; Bidnur S; Khalaf D; Chavez-Munoz C; Struss W; Eigl BJ; Gleave M; Chi KN; So A
World J Urol; 2018 Jul; 36(7):1039-1046. PubMed ID: 29488095
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
[TBL] [Abstract][Full Text] [Related]
7. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
Whitney CA; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Cancer; 2016 Dec; 122(24):3848-3855. PubMed ID: 27505036
[TBL] [Abstract][Full Text] [Related]
8. The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases.
O'Hurley G; Prencipe M; Lundon D; O'Neill A; Boyce S; O'Grady A; Gallagher WM; Morrissey C; Kay EW; Watson RW
Prostate; 2014 Feb; 74(3):306-13. PubMed ID: 24249383
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
10. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
[TBL] [Abstract][Full Text] [Related]
11. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
[TBL] [Abstract][Full Text] [Related]
12. Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?
Zhao T; Liao B; Yao J; Liu J; Huang R; Shen P; Peng Z; Gui H; Chen X; Zhang P; Zhu Y; Li X; Wei Q; Zhou Q; Zeng H; Chen N
Prostate; 2015 Feb; 75(3):225-32. PubMed ID: 25307858
[TBL] [Abstract][Full Text] [Related]
13. Selective lymph node dissection for castration-resistant prostate cancer.
Busch J; Hinz S; Kempkensteffen C; Erber B; Klopf C; Weikert S; Miller K; Magheli A
Urol Int; 2012; 88(4):441-6. PubMed ID: 22398510
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
Stege R; Grande M; Carlström K; Tribukait B; Pousette A
Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
[TBL] [Abstract][Full Text] [Related]
15. Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in Sweden.
Banefelt J; Liede A; Mesterton J; Stålhammar J; Hernandez RK; Sobocki P; Persson BE
Cancer Epidemiol; 2014 Aug; 38(4):442-7. PubMed ID: 24875326
[TBL] [Abstract][Full Text] [Related]
16. Current state of castration-resistant prostate cancer.
Petrylak DP
Am J Manag Care; 2013 Dec; 19(18 Suppl):s358-65. PubMed ID: 24494690
[TBL] [Abstract][Full Text] [Related]
17. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
[TBL] [Abstract][Full Text] [Related]
18. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
19. The impact of diabetes mellitus on survival in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.
Shetti MB; Merrick GS; Butler WM; Galbreath R; Torlone A; Lief JH; Adamovich E; Wallner KE
Am J Clin Oncol; 2012 Dec; 35(6):572-9. PubMed ID: 22134514
[TBL] [Abstract][Full Text] [Related]
20. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
